Moderna Holders Are Up 884% And Here Is What They Saw

For Moderna shareholders, the return over the past year was 883.9%, including dividends. If you had been weighing a buy on 5 November 2025, you were looking at a biotechnology specialist wrestling with shrinking COVID demand, cost cuts and heavy losses, while bulls pointed to oncology trials, AI-driven R&D and an mRNA pipeline that might broaden far beyond vaccines. Which side of that debate would you have backed with real money?

Moderna has already moved. Pinpoint other ways to investigate the theme among 34 healthcare AI stocks.

The Two Competing Stories Around Moderna

The shares cost US$23.56 at the start of the period, and anyone looking at Moderna then had to decide which of two very different stories felt more realistic.

On the bullish side, one camp argued the stock was worth a Fair Value of US$44.25, a notional price based on their assumptions about the future. That view leaned on expected revenue growth of 4.6% a year and profit margins moving toward 14.2% over roughly three years.

The bearish camp saw things very differently. Their Fair Value sat at US$18.15 and reflected concerns that revenue might fall 16.4% a year while Moderna remained dependent on a shrinking and volatile COVID vaccine market.

What The Results And Trials Did To The Moderna Debate

Moderna’s melanoma vaccine with Merck reported Phase 3 data showing a 42% cut in recurrence or death risk, while Q2 2026 results showed revenue at US$145 million and the loss narrowing to US$782 million. The oncology and vaccine approvals backed the optimistic diversification story, but ongoing losses meant the profitability part of that bull case stayed unproven.

The lesson for readers is clear. When a growth story hinges on new products, track two things separately: pipeline milestones by therapy area, and the reported profit trend that is meant to follow.

What Moderna’s Price Now Assumes

Today Moderna changes hands at US$241, a level reached after a very large gain over the past year. The selected Narrative’s Fair Value sits below the current price and frames that gap around how much future vaccine, oncology and rare liver disease success is already embedded into expectations.

On this view, anyone paying today’s price is effectively betting that cancer vaccines and rare liver programs scale as hoped, with manufacturing kept on track. The question is how that assumption holds up if individualized intismeran production or broader liver franchise execution prove slower or more complex than projected.

"The main requirement is successful execution on individualized and shared-antigen cancer vaccines and liver-targeted mRNA therapies, including managing complex manufacturing for intismeran and bringing additional rare disease programs into the clinic while scaling production capacity."

One Narrative has put a figure on that disagreement. → See the Narrative with its lower Fair Value, assumptions and all

Beyond Moderna’s mRNA Story

Moderna highlights one major healthcare shift, but chronic diseases and obesity still shape many everyday treatment decisions.

Another large drug maker is leaning into that need, focusing on cardiometabolic health, cancer and immune disorders.

It sells treatments for diabetes, weight management and migraine, while moving deeper into neurology and vaccines.

That toolkit targets conditions most health systems already prioritize today.

This business is also buying platforms in genetic medicine and emerging brain therapies, so a simple obesity thesis could touch a much wider therapeutic map.

That argument has a Narrative and a number behind it. → See the company one Narrative values 21% above its price

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com